抗纤益心方对扩张型心肌病大鼠血浆血管紧张素Ⅱ和醛固酮的影响  

Effects of Kangxian Yixin Formula on Plasma Angiotensin Ⅱ and Aldosterone in Rats with Dilated Cardiomyopathy

作　　者：魏景梅[1] 王振涛[1] 柴松波[1] 李伯海[1] 

机构地区：[1]河南省中医院心血管病研究室,郑州450011

出　　处：《中国实验方剂学杂志》2011年第13期195-197,共3页Chinese Journal of Experimental Traditional Medical Formulae

基　　金：河南省高校新世纪优秀人才支持计划(2005HANCET-07)

摘　　要：目的:探讨抗纤益心方抑制扩张型心肌病(DCM)大鼠血浆血管紧张素Ⅱ和醛固酮的机制。方法:采用自主饮用呋喃唑酮水溶液(按1 kg水加700 mg呋喃唑酮配置)建立DCM大鼠模型,分为模型组、抗纤益心方高、低剂量组、卡托普利对照组、中西药联用组。每日分别给予生理盐水,抗纤益心方18.8,4.7 g·kg-1,卡托普利10.125 mg·kg-1,抗纤益心方高剂量和卡托普利混合溶液,ig干预8周,用放射免疫法检测血浆血管紧张素Ⅱ和醛固酮含量。结果:模型组大鼠血浆中血管紧张素Ⅱ(159.94±12.03)ng·L-1和醛固酮(1.23±0.09)μg·L-1明显高于正常组(69.47±7.79)ng·L-1和(0.34±0.11)μg·L-1(P<0.05);与模型组比较,所有给药组(抗纤益心方小剂量组除外)血浆中血管紧张素Ⅱ和醛固酮明显下降(P<0.05);抗纤益心方18.8 g·kg-1组与卡托普利10.125 mg·kg-1组相比无显著差异,血管紧张素Ⅱ分别为(85.23±5.18),(87.90±6.02)ng·L-1,醛固酮分别为(0.69±0.06),(0.74±0.42)μg·L-1(P>0.05),与中西药联用组比较有统计学意义(P<0.05),与小剂量组比较有显著差异(P<0.05)。结论:抗纤益心方能够干预扩张型心肌病大鼠左室重构,其作用可能与抑制血浆中血管紧张素Ⅱ及醛固酮的水平有关。Objective：To investigate the mechanism of Kangxian Yixin Formula（KXYXF）for inhibiting plasma aldosterone and angiotensin Ⅱin rats with dilated cardiomyopathy（DCM）.Method： Free drinking of furazolidone solution（700 mg furazolidone in 1kg of water）was used to establish DCM in rats.The rats were divided into model group,KXYXF high-dose group,KXYXF low-dose group,captopril control group.KXYXF combined with captopril group.The rats were accordingly treated daily with normal saline,KXYXF 18.8 g·kg-1,KXYXF 4.7 g·kg-1,captopril 10.125 mg·kg-1,KXYXF 18.8 g·kg-1combined with captopril 10.125 mg·kg-1ig for 8 weeks.Plasma angiotensin Ⅱ and aldosterone were determined by radioimmunoassay.Result： Aldosterone and plasma Ang Ⅱ were higher in the model group and compared with those in normal group[（159.94±12.03） vs（69.47±7.79） ng·L-1 and（1.23±0.09） vs（0.34±0.11） μg·L-1accordingly,both P0.05].Compared with the model group,angiotensin Ⅱ and aldosterone in all treated groups（except KXYXF low dose group）were significantly decreased（P0.05）;while the KXYXF high-dose group and the captopril group showed no significant difference（85.23±5.18） vs（87.90±6.02） ng·L-1 and（0.69±0.06） vs（0.74±0.42） μg·L-1 respectively）.The KXYXF combined with captopril group showed statistically significant（P0.05）,the KXYXF low dose group was also significant（P0.05）.Conclusion： KXYXF can interfere with dilated left ventricular remodeling in rats with dilated cardiomyopathy（DCM）.This may be related to the inhibition of plasma angiotensin Ⅱ and aldosterone.

关 键 词：抗纤益心方 扩张型心肌病 心室重构 血管紧张素Ⅱ 醛固酮 

分 类 号：R285.5[医药卫生—中药学]